MedTrace Logo

Acute Application of Pegvisomant and Octreotide in Acromegaly

NCT00595140 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2008-04-01

No results posted yet for this study

Summary

The purpose of the study is to investigate the efficacy of an acute additional application of the somatostatin analogue octreotide 100µg s.c. or the dopamine agonist cabergoline 0.5mg p.o. to the receptor antagonist pegvisomant during a 6 or 9 hour profile on reducing endogenous growth hormone in patients with acromegaly on stable pegvisomant therapy.

Conditions

Interventions

DRUG

pegvisomant

growth hormone receptor antagonist pegvisomant in patients´ individual dose

DRUG

combination with somatostatin analogue octreotide

s.c., 100µg, one time

DRUG

combination with dopamine agonist cabergoline

oral, 0.5mg, one time

Sponsors & Collaborators

  • Ludwig-Maximilians - University of Munich

    lead OTHER

Principal Investigators

  • Jochen Schopohl, MD · Medizinische Klinik - Innenstadt

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2008-03-31
Completion
2008-03-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00595140 on ClinicalTrials.gov